Lubiprostone, also known as RU-0211, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006. Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).
Related Prodcuts: (+)-Cloprostenol; Cloprostenol; Misoprostol; Carboprost; Travoprost; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Iloprost; Limaprost; Bimatoprost; Latanoprost; Lubiprostone hemiketal; Lubiprostone Intermediate